Iranian
Biomedical Journal
Volume 30, Issue 1 (1-2026)
IBJ 2026, 30(1): 59-66 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bayat S, Mousavi N, Vand-Rajabpour F, Mamivand A, Tabrizi M, Khoshnevisan A. Expression of Epithelial-Mesenchymal Transition-Related Genes in Primary Brain Tumors. IBJ 2026; 30 (1) :59-66
URL: http://ibj.pasteur.ac.ir/article-1-5133-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5133-en.html
Shiva Bayat 
, Negar Mousavi , Fatemeh Vand-Rajabpour , Ali Mamivand , Mina Tabrizi * , Alireza Khoshnevisan
, Negar Mousavi , Fatemeh Vand-Rajabpour , Ali Mamivand , Mina Tabrizi * , Alireza Khoshnevisan
Abstract:
Background: Gliomas are the most common malignant primary brain tumors in adults. Meningiomas, on the other hand, are benign primary brain tumors treated by surgical resection. Epithelial-to-mesenchymal transition (EMT), stemness, and leader behavior are among the most important complex processes contributing to tumor progression and aggressiveness. Thus, the evaluation of molecular targets involved in the EMT processes in primary brain tumors can help elucidate the molecular mechanisms underlying glioma aggressiveness, ultimately identifying potential areas for further research.
Methods: We conducted expression analysis of zinc finger E-box homeobox 1 (ZEB1), Sry-related HMG box (SOX2), and p21 in 31 glioma (15 glioblastoma [GBM] and 16 non-GBM) and 44 meningioma samples using quantitative real-time PCR. We also compared expression levels between glioma and meningioma, as well as between GBM and non-GBM tumor samples.
Results: The expression levels of SOX2 and ZEB1 showed a significant increase in gliomas compared to meningiomas (p = 0.016 and 0.017, respectively). However, p21 did not reveal any significant difference in expression between the two groups. Notably, p21 was the only gene that exhibited a significant increase in expression in GBM samples compared to non-GBM samples, with a p value of 0.027.
Conclusion: Our results suggest that SOX2 and ZEB1 expression levels have a significant role in glioma progression. Interestingly, based on the elevated p21 expression level in the GBM, we also suggest that aggressive tumor features arise from distinct molecular mechanisms depending on tumor subtype, not a single universal pathway.
Methods: We conducted expression analysis of zinc finger E-box homeobox 1 (ZEB1), Sry-related HMG box (SOX2), and p21 in 31 glioma (15 glioblastoma [GBM] and 16 non-GBM) and 44 meningioma samples using quantitative real-time PCR. We also compared expression levels between glioma and meningioma, as well as between GBM and non-GBM tumor samples.
Results: The expression levels of SOX2 and ZEB1 showed a significant increase in gliomas compared to meningiomas (p = 0.016 and 0.017, respectively). However, p21 did not reveal any significant difference in expression between the two groups. Notably, p21 was the only gene that exhibited a significant increase in expression in GBM samples compared to non-GBM samples, with a p value of 0.027.
Conclusion: Our results suggest that SOX2 and ZEB1 expression levels have a significant role in glioma progression. Interestingly, based on the elevated p21 expression level in the GBM, we also suggest that aggressive tumor features arise from distinct molecular mechanisms depending on tumor subtype, not a single universal pathway.
Type of Study: Full Length/Original Article |
Subject:
Cancer Biology
References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. [DOI:10.1007/s00401-007-0243-4]
2. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(2):1-56. [DOI:10.1093/neuonc/not151]
3. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403-13. [DOI:10.1215/15228517-2008-097]
4. Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010;48(2):145-52. [DOI:10.3340/jkns.2010.48.2.145]
5. Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9(3):319-25. [DOI:10.1215/15228517-2007-016]
6. Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M, et al. Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005-2007. Neuroepidemiology. 2009;33(2):89-95. [DOI:10.1159/000222090]
7. Bradshaw A, Wickremsekera A, Tan ST, Peng L, Davis PF, Itinteang T. Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg. 2016;3;21. [DOI:10.3389/fsurg.2016.00021]
8. Sheehan J, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010;6(10):1591-601. [DOI:10.2217/fon.10.123]
9. Jampani P, Venkatesh BS, Sujan KC, Kabindra K. Review on glioblastoma multiforme (GBM). World J Pharm Res.2018;7(17):326-37.
10. Paw I, Carpenter RC, Watabe K, Debinski W, Lo H-W. Mechanisms regulating glioma invasion. Cancer Lett. 2015;362(1):1-7. [DOI:10.1016/j.canlet.2015.03.015]
11. Iwadate Y. Epithelial mesenchymal transition in glioblastoma progression. Oncol Lett. 2016;11(3):1615-20. [DOI:10.3892/ol.2016.4113]
12. Nørøxe DS, Poulsen HS, Lassen U. Hallmarks of glioblastoma: A systematic review. ESMO Open. 2017;1(6):000144. [DOI:10.1136/esmoopen-2016-000144]
13. Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16(9):864-75. [DOI:10.1038/ncb3013]
14. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-28. [DOI:10.1038/nrc2131]
15. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, et al. The transcription factor ZEB1 (deltaEF1) promotes tumor cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007;26(49):6979-88. [DOI:10.1038/sj.onc.1210508]
16. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan, A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008;68(2):537-44. [DOI:10.1158/0008-5472.CAN-07-5682]
17. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl, D, Sarkisian, MR, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 2013;5(8):1196-212. [DOI:10.1002/emmm.201302827]
18. Kozyrska K, Pilia G, Vishwakarma M, Wagstaff L, Goschorska M, Cirillo S, et al. P53 directs leader cell behavior, migration, and clearance during epithelial repair. Science. 2022;375(6581):8876. [DOI:10.1126/science.abl8876]
19. Gross MW, Kraus A, Nashwan K, Mennel H-D, Engenhart-Cabillic R, Schlegel J. Expression of p53 and p21 in Primary Glioblastomas. Strahlenther Onkol. 2005;181(3):164-71. [DOI:10.1007/s00066-005-1304-z]
20. Terzi A, Saglam EA, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract. 2008;204(5):305-14. [DOI:10.1016/j.prp.2008.01.013]
21. Annovazzi L,Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics. 2011;8(3):139-48.
22. Xiao Z-Y, Chen X-J, Pan Q, Yang Q-Z, Li K-Z. Expression of nestin, CD133 and Sox2 in meningiomas. Turk Neurosurg. 2018;28(6):910-14.
23. Nesvick CL, Zhang C, Edwards NA, Montgomery BK, Lee M, Yang C, et al. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. J Neurooncol. 2016;130(1):111-22. [DOI:10.1007/s11060-016-2240-8]
24. Wallesch M, Pachow D, Blucher C, Firsching R, Warnke J-P, Braunsdorf WEK, et al. Altered expression of E-cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas. J Neurol Sci. 2017:380:112-21. [DOI:10.1016/j.jns.2017.07.009]
25. Said HM, Hagemann C, Stojic J, Schoemig B, Vince, GH, Flentje M, et al. GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol. 2007:8:55. [DOI:10.1186/1471-2199-8-55]
26. Mathur D. Selection of suitable housekeeping genes for expression analysis in glioblastoma using qRT-PCR. Ann Neurosci. 2014;21(2):62-3.
27. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3(12):895-902. [DOI:10.1038/nrc1232]
28. Ahmadi-Beni R, Vand-Rajabpour F, Ahmadifard M, Daneshpazhooh M, Noormohammadpour P, Rahmati J, et al. Decreased Sox2 messenger RNA expression in basal cell carcinoma. Indian J Dermatol. 2020;65(3):178-82. [DOI:10.4103/ijd.IJD_387_18]
29. Han X, Fang X, Lou X, Hua D, Ding W, Foltz G, et al. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. Plos One. 2012;7(8):41335. [DOI:10.1371/journal.pone.0041335]
30. Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell. 2014;26(1):33-47. [DOI:10.1016/j.ccr.2014.05.005]
31. Berezovsky AD, Poisson LM, Cherba D, Webb CP, Mikkelsen AD, deCarvalho AC. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia. 2014;16(3):193-206. [DOI:10.1016/j.neo.2014.03.006]
32. Shivapathasundram G, Wickremesekera AC, Brasch HD, Marsh R, Tan ST, Itinteang T. Expression of embryonic stem cell markers on the microvessels of WHO grade I meningioma. Front Surg. 2018;(5):65. [DOI:10.3389/fsurg.2018.00065]
33. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh, M, Shroyer KR, et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006;66(7):3893-902. [DOI:10.1158/0008-5472.CAN-05-2881]
34. Wellner U, Brabletz T, Keck T. ZEB1 in pancreatic cancer. Cancers. 2010;2(3):1617-28. [DOI:10.3390/cancers2031617]
35. Shen A, Zhang Y, Yang H, Xu R, Huang G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol. 2012;105(8):830-4. [DOI:10.1002/jso.23012]
36. Zhang J, Lu C, Zhang J, Kang J, Cao C, Li M. Involvement of ZEB1 and E-cadherin in the invasion of lung squamous cell carcinoma. Mol Biol Rep. 2013;40(2):949-56. [DOI:10.1007/s11033-012-2136-4]
37. Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, Yin ZF, et al. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 2012;19(5):1700-6. [DOI:10.1245/s10434-011-1772-6]
38. Okugawa Y, Toiyama Y, Tanaka K, Matsusita K, Fujikawa H, Saigusa S, et al. Clinical significance of zinc finger E‐box binding homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol. 2012;106(3):280-5. [DOI:10.1002/jso.22142]
39. Edwards LA, Kim S, Madany M, Nuno M, Thomas T, Li A, et al. ZEB1 is a transcription factor that is prognostic and predictive in diffuse gliomas. Front Neurol. 2019:9:1199. [DOI:10.3389/fneur.2018.01199]
40. Edwards LA, Li A, Berel D, Madany M, Kim N-H, Liu M, et al. ZEB1 regulates glioma stemness through LIF repression. Sci Rep. 2017;7(1):69. [DOI:10.1038/s41598-017-00106-x]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |